Supplements and Featured Publications, The Economic Burden of Stroke in Atrial Fibrillation, Volume 10, Issue 14 Suppl

The Economic Burden of Stroke in Atrial Fibrillation

The American Journal of Managed Care

This supplement to contains information about optimalanticoagulation therapy to avoid the morbidity and mortality associated with stroke in patients withatrial fibrillation, contain costs, and preserve healthcare resources.

Gregory W. Albers, MD

Professor of Neurology and Neurological Sciences

Director, Stanford Stroke Center

Member, SPORTIF Executive Steering Committee

Stanford University Medical Center

Palo Alto, California

J. Jamie Caro, MDCM, FRCPC, FACP

Scientific Director

Caro Research

Concord, Massachusetts

Kenneth L. Schaecher, MD

Medical Director

Utilization Management

Intermountain Healthcare

West Valley City, Utah

Disclosure Statement

In accordance with the ACCME and the ACPE, participants for this activity have completed a conflict-of-interest disclosure statement.

In compliance with the Health Insurance Portability and Accountability Act standards, no presentationsin this CME/CE activity shall disclose the names or other unique identifiers of patients referenced withouta signed waiver from the identified patient.

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programssponsored by corporate organizations disclose any real or apparent conflicts of interest.

These participants have declared the following relationships with corporate organizations:

  • Gregory W. Albers, MDGrant/Research Support From:AstraZenecaBristol-Myers SquibbSanofi-AventisGrant Support From/Consultant To/Speaker For:Boehringer Ingelheim

  • J. Jamie Caro, MDCM, FRCPC, FACPGrant/Research Support From:AstraZenecaBristol-Myers SquibbPharmaciaSanofi-Aventis

  • Kenneth L. Schaecher, MDConsultant To:AstraZenecaWyeth

NOTE: The Food and Drug Administration (FDA) Cardiovascular & Renal Drugs Advisory Committee voted against recommending approval for ximelagatran (Exanta) for all 3 indications under review at the FDA. These indications include: prevention of stroke and other thromboembolic complications associated with atrial fibrillation; secondary prevention of venous thromboembolism (VTE) after standard treatment for an acute episode; and short-term prevention of VTE in patients undergoing knee replacement surgery. The committee agreed that the risk management plan offered by the drug's manufacturer, AstraZeneca, did not seem adequate to prevent severe liver damage. Another concern was the number of adverse cardiac events, such as myocardial infarction, possibly associated with using ximelagatran for knee replacement surgery. However, these concerns could be addressed with further safety studies. AstraZeneca is continuing discussions with the FDA.

The American Journal of Managed Care,

Signed disclosures are on file at the offices of Jamesburg, New Jersey.